Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 10/20 | 0.46 |
| ▸ | PDE4A | P27815 | 9/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363498 | 0.85 | STING1 (0.52) | STING1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1364020 | 0.85 | UMPS (0.48) | STING1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3219336 | 0.83 | UMPS (0.52) | STING1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15189724 | 0.81 | UMPS (0.54) | STING1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3203326 | 0.79 | DHFR (0.56) | STING1 | |
| SCHEMBL3220715 | 0.78 | PDE4A (0.48) | STING1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1363178 | 0.77 | PDE4A (0.48) | STING1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8537224 | 0.77 | STING1 (0.56) | STING1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1364784 | 0.74 | PDE4A (0.50) | STING1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1363426 | 0.74 | PDE4A (0.50) | STING1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | claimed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | claimed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | disclosed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | DPYD, TYMP, TYMS | STING1 598/4885PDE4A 2919/4885PDE4B 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.